Sravanti Rangaraju

Title: Sravanti Rangaraju: Innovator in Graft Versus Host Disease Management

Introduction

Sravanti Rangaraju is a notable inventor based in Atlanta, GA (US). He has made significant contributions to the field of medical science, particularly in the management of graft versus host disease (GvHD). With a total of 2 patents, his work is paving the way for innovative treatments in hematological malignancies.

Latest Patents

Rangaraju's latest patents include methods of managing graft versus host disease using indole carboxyaldehydes or derivatives thereof. In certain embodiments, this disclosure relates to methods of treating or preventing GvHD by administering an effective amount of indole-2-carboxyaldehyde, indole-3-carboxyaldehyde, or their derivatives to a subject in need. Additionally, he has developed methods for treating subjects with hematological malignancies or other cancers by transplanting allogenic bone marrow or stem cells in combination with administering these compounds. Another significant patent focuses on the use of drugs to prevent GvHD in subjects undergoing hematopoietic stem cell transplants, particularly targeting vasoactive intestinal peptide signaling.

Career Highlights

Sravanti Rangaraju is affiliated with Emory University, where he continues to advance research in his field. His innovative approaches to treating GvHD have garnered attention and recognition within the medical community.

Collaborations

Rangaraju collaborates with esteemed colleagues such as Edmund K. Waller and Cynthia R. Giver, who contribute to the research and development of his groundbreaking work.

Conclusion

Sravanti Rangaraju's contributions to the management of graft versus host disease represent a significant advancement in medical science. His innovative patents and collaborations are set to improve treatment outcomes for patients facing hematological malignancies.